BIENAIME JEAN JACQUES 4

What Happened

• Bienaime Jean Jacques, a director of Keros Therapeutics (KROS), purchased 2,000 shares in an open-market/private purchase (code P) on 2026-03-09.
• The weighted average price was $11.21 per share, for a reported total of $22,420. Reported prices ranged from $10.98 to $11.48 across multiple trades (see footnote F2). This was a purchase (insider buying is often considered more informative than routine selling).

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (no late filing indicated in provided data).
• Price: weighted average $11.21; trade price range $10.98–$11.48 (multiple executions).
• Shares acquired: 2,000; total reported value: $22,420.
• Shares owned after transaction: not reported in the information provided.
• Notable footnotes:
  • F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted Dec 5, 2025 (pre-established plan).
  • F2: Price is a weighted average; the filer can provide per-trade breakdown on request.

Context

• A 10b5-1 plan indicates these trades were made under a pre-established trading arrangement, which can limit the extent to which the purchase reflects the insider’s immediate view of the company.
• The purchase size (~$22.4k) is relatively modest; investors often weigh such buys alongside other insider activity and company fundamentals.